Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Lung Cancer Therapeutics Market Size, Share, Research: By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Others; By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Others; By End Use; By Distribution Channels; Regional Analysis; Competitive Landscape; 2022-2027

Global Lung Cancer Therapeutics Market Outlook

The global lung cancer therapeutics market size is expected to grow at a CAGR of 10.10% during the forecast period of 2022-2027. This growth can be attributed to various companies launching new and innovative treatments for cancer, aided by technological advancements.

 

Global Lung Cancer Therapeutics Market Trends

Cancer refers to multiple tumours that can start developing in one of the body parts and spread uncontrollably to other parts of the body. Tumours are lumps of tissue which are often identified as the initial symptoms of cancer. In the later stages, when the cancerous cells spread abnormally to other organs, it becomes extremely difficult to treat them. This process is known as metastasis.

 

One of the primary causes of lung cancer is smoking. It can also happen due to using other types of tobacco and inhaling secondhand smoke or due to genetic factors.

 

Increasing Population of Smokers

The number of people smoking and adopting unhealthy lifestyles has become one of the major factors for the rising prevalence of lung cancer patients.

 

Development of Advanced Treatments

The development of advanced targeted treatments such as chemotherapy and radiation therapy. Moreover, with the FDA approving immunotherapy for lung cancer treatment, the market is likely to witness further growth in the forecast period.

 

Growing Focus on Research and Development

Companies have started to invest in research and development teams and collaborate with institutes to study and develop innovative treatment methods. This can further bolster the market growth in the coming years.

 

Increasing Investments by the Government

Governments of different countries have started investing in the infrastructural development of the healthcare sector and promoting treatment services. This can augment the market growth as the awareness among people rises.

 

Opportunities for the Global Lung Cancer Therapeutic Market

Implementation of Machine Learning

Companies have started to combine cancer treatment with machine learning. This will help the specialists identify cancer more efficiently with the CT scans.

 

Increasing Disposable Income

The rapid industrialisation in developing countries has propelled the disposable incomes of the population, which can augment the healthcare market and show positive opportunities for the expansion of lung cancer therapeutics.

 

Nanomedicine for Targeted Treatment

The development and implementation of nanomedicine can open up new opportunities for the market players and further propel the market development. This method of treatment will target the specific cancer cells for treatment and reduce the adverse effects of therapeutics.

 

Major Challenges for the Global Lung Cancer Therapeutic Market Development

Lack of Skilled Professionals

Cancer therapeutics and technologies require skilled and trained professionals for the proper management of the systems.

 

High Maintenance Costs for the Devices

The devices for cancer therapeutics require extensive amounts of money for maintenance and installation, which can be a hindering factor as smaller health institutions would avoid investing in these technologies.

 

Unequal Distribution of Cancer Care

Inadequate infrastructure and standardisation can hinder cancer care delivery, ultimately hindering the market growth.

 

Global Lung Cancer Therapeutics Market Analysis

Based on type, the market can be segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among others. Based on the therapy, it can be bifurcated into chemotherapy, immunotherapy, radiation therapy, and targeted therapy, among others. Based on end-use, the market segments include hospitals, home care, and speciality clinics, among others. Based on distribution channels, the marker segments include hospital pharmacies, retail pharmacies, and online.

 

The regional markets for the lung therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

The extensive E.M.R. report provides an in-depth evaluation of the market based on Porter's five forces model and a SWOT analysis

 

The lung cancer therapeutics market report comprehensively analyses key players in the market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.

 

  • Genentech, Inc.
  • AstraZeneca PLC
  • Novartis AG.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Others

 

Different Types of Lung Cancer

Based on type, the market segments include non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Non-small cell lung cancer develops at a slower rate than small-cell lung cancer. The cancer cells in this type are larger compared to the other type. It is the most common type of lung cancer, accounting for a major percentage of lung cancer cases.

 

Small-cell lung cancer spreads faster than non-small cell lung cancer and there are chances that this type of cancer can come back after treatment. This type of lung cancer is the least common type of lung cancer.

 

Different Therapies Available in the Market

Based on therapies, chemotherapy and radiation therapy hold a significant share of the market as they are the primary type of treatment given to patients. Chemotherapy is a type of cancer treatment conducted by using powerful drugs to kill fast-spreading cells or reduce the symptoms and prolong life.

 

Radiation therapy involves doses of radiation to kill cancer cells or slow down their growth by damaging their DNA. The treatment focuses on a particular body part where cancer cells are present.

 

Other treatments include immunotherapy and targeted therapy. Immunotherapy treatment utilises our body’s own immune system’s capabilities to control and treat cancer. It conditions our immune system to identify and attack cancer cells. It strengthens our immune system to fight against cancer cells if they return.

 

Targeted therapy as a type of cancer treatment utilises drugs to target the specific cells and proteins which help in the growth of cancer.

 

These Therapeutics Find End-Uses in Hospitals, Home Care, and Speciality Clinics

The lung cancer therapeutics market has several end-users including hospitals, homecare, and speciality clinics, among others. Among these segments, hospitals hold the largest share of the market.

 

With developing health infrastructure, larger hospitals are equipped with the latest technologies such as Gamma Cameras, PET/CT, CT simulation, and MRI (Magnetic Resonance Imaging), among others, for the diagnosis and treatment of cancer.

 

Cancer homecare is a specialised care service provided to patients as they deal with a lot of side effects. This service allows the patients to stay in a familiar environment with their families while receiving care from specialist.

 

Cancer speciality clinics are centres with specialised equipment and trained staff for the treatment of different types of cancer. Many developing countries are developing specialised clinics due to the increasing number of cases.

 

Distribution Channels include Hospital Pharmacies, Retail Pharmacies, and Online Channels

Based on distribution channels, the market segments include retail pharmacies, hospital pharmacies, and online pharmacies. Among these distribution channels, hospital pharmacy is expected to hold a significant share due to the increasing number of cases in hospitals.

 

Retail pharmacies are also growing in the market owing to the increasing preference of people to buy medicine from nearby stores. Online pharmacy is expected to hold a higher growth rate due to the rapid growth of the e-commerce industry.

 

Competitive Landscape

Genentech, Inc. is a biotechnology company based in the United States. They became a part of the Roche Group in March of 2009. They function independently within Roche.

 

They have been developing medicines for chronic and life-threatening diseases. Some of their major developments were treatment for locally advanced or metastatic non-small lung cancer and pancreatic cancer, and designed antibodies to stop the activation and reactivation of T-cells that cause psoriasis.

 

AstraZeneca PLC is a multinational company working in the field of pharmaceuticals and biotechnology, with a focus on developing and commercialising prescription medicines. Their areas for medicine development include Oncology, Cardiovascular and Metabolic Disease (CVMD) and Respiratory. They also collaborate with biotech research institutes to work with emerging technologies such as Modified RNA and CRISPR genome editing.

 

Novartis AG. is a Swiss multinational pharmaceutical company with a focus on creating treatments with science and technology in various sectors such as oncology, ophthalmology, neuroscience, and cardiovascular disorders, among many others. Novartis is also engaged in radioligand therapy, precision imaging, and gyroscope therapeutics.

 

Merck KGaA is a multinational company for science and technology with operations in different sectors such as healthcare, life science and electronics. They design and develop medicines and smart devices to treat diseases such as cancer and multiple sclerosis.

 

F. Hoffmann-La Roche Ltd is more commonly known as Roche. It is a multinational healthcare company based in Switzerland. They operate worldwide focusing on two sectors pharmaceuticals and diagnostics. They have started to focus on personalised healthcare with early detection of diseases and accurate diagnosis.

 

Boehringer Ingelheim International GmbH is a leading biopharmaceutical company, working with professionals on the latest innovation for the diagnosis of diseases for human health. The company works on drug discovery and development, and other healthcare products for heart diseases, metabolic diseases, cancer, lung diseases, mental disorders, and retinal diseases.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Cancer Type
  • Therapy
  • End Use
  • Distribution Channels
  • Region
Breakup by Cancer Type
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer (SCLC)
  • Others
Breakup by Therapy
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Others
Breakup by End Use
  • Hospitals
  • Homecare
  • Speciality Clinics
  • Others
Breakup by Distribution Channels
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Genentech, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Lung Cancer Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Lung Cancer Therapeutics Historical Market (2017-2021) 
    8.3    Global Lung Cancer Therapeutics Market Forecast (2022-2027)
    8.4    Global Lung Cancer Therapeutics Market by Cancer Type
        8.4.1    Non-Small Cell Lung Cancer
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Small Cell Lung Cancer (SCLC)
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Others
    8.5    Global Lung Cancer Therapeutics Market by Therapy
        8.5.1    Chemotherapy
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Immunotherapy
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Radiation Therapy
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Targeted Therapy
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Others
    8.6    Global Lung Cancer Therapeutics Market by End Use
        8.6.1    Hospitals
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Homecare
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
        8.6.3    Speciality Clinics
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2017-2021)
            8.6.3.3    Forecast Trend (2022-2027)
        8.6.4    Others
    8.7    Global Lung Cancer Therapeutics Market by Distribution Channels
        8.7.1    Hospital Pharmacy
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2017-2021)
            8.7.1.3    Forecast Trend (2022-2027)
        8.7.2    Retail Pharmacy
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2017-2021)
            8.7.2.3    Forecast Trend (2022-2027)
        8.7.3    Online
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2017-2021)
            8.7.3.3    Forecast Trend (2022-2027)
    8.8    Global Lung Cancer Therapeutics Market by Region
        8.8.1    North America
            8.8.1.1    Market Share
            8.8.1.2    Historical Trend (2017-2021) 
            8.8.1.3    Forecast Trend (2022-2027)
        8.8.2    Europe
            8.8.2.1    Market Share
            8.8.2.2    Historical Trend (2017-2021) 
            8.8.2.3    Forecast Trend (2022-2027)
        8.8.3    Asia Pacific
            8.8.3.1    Market Share
            8.8.3.2    Historical Trend (2017-2021) 
            8.8.3.3    Forecast Trend (2022-2027)
        8.8.4    Latin America
            8.8.4.1    Market Share
            8.8.4.2    Historical Trend (2017-2021) 
            8.8.4.3    Forecast Trend (2022-2027)
        8.8.5    Middle East and Africa
            8.8.5.1    Market Share
            8.8.5.2    Historical Trend (2017-2021) 
            8.8.5.3    Forecast Trend (2022-2027)
9    North America Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2017-2021) 
        9.1.3    Forecast Trend (2022-2027)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2017-2021) 
        9.2.3    Forecast Trend (2022-2027)
10    Europe Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2017-2021) 
        10.1.3    Forecast Trend (2022-2027)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2017-2021) 
        10.2.3    Forecast Trend (2022-2027)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2017-2021) 
        10.3.3    Forecast Trend (2022-2027)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2017-2021) 
        10.4.3    Forecast Trend (2022-2027)
    10.5    Others
11    Asia Pacific Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2017-2021) 
        11.1.3    Forecast Trend (2022-2027)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2017-2021) 
        11.2.3    Forecast Trend (2022-2027)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2017-2021) 
        11.3.3    Forecast Trend (2022-2027)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2017-2021) 
        11.4.3    Forecast Trend (2022-2027)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2017-2021) 
        11.5.3    Forecast Trend (2022-2027)
    11.6    Others
12    Latin America Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2017-2021) 
        12.1.3    Forecast Trend (2022-2027)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2017-2021) 
        12.2.3    Forecast Trend (2022-2027)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2017-2021) 
        12.3.3    Forecast Trend (2022-2027)
    12.4    Others
13    Middle East and Africa Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2017-2021) 
        13.1.3    Forecast Trend (2022-2027)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2017-2021) 
        13.2.3    Forecast Trend (2022-2027)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2017-2021) 
        13.3.3    Forecast Trend (2022-2027)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2017-2021) 
        13.4.3    Forecast Trend (2022-2027)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Genentech, Inc.
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    AstraZeneca PLC
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Novartis AG
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Merck KGaA
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    F. Hoffmann-La Roche Ltd
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    Boehringer Ingelheim International GmbH
            15.2.6.1    Company Overview
            15.2.6.2    Product Portfolio
            15.2.6.3    Demographic Reach and Achievements
            15.2.6.4    Certifications
        15.2.7    Others
16    Key Trends and Developments in the Market

 

List of Figures and Tables

1.    Global Lung Cancer Therapeutics Market: Key Industry Highlights, 2017 and 2027
2.    Global Lung Cancer Therapeutics Historical Market: Breakup by Cancer Type (USD Million), 2017-2021
3.    Global Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (USD Million), 2022-2027
4.    Global Lung Cancer Therapeutics Historical Market: Breakup by Molecular Type (USD Million), 2017-2021
5.    Global Lung Cancer Therapeutics Market Forecast: Breakup by Molecular Type (USD Million), 2022-2027
6.    Global Lung Cancer Therapeutics Historical Market: Breakup by Drug Class (USD Million), 2017-2021
7.    Global Lung Cancer Therapeutics Market Forecast: Breakup by Drug Class (USD Million), 2022-2027
8.    Global Lung Cancer Therapeutics Historical Market: Breakup by Therapy Type (USD Million), 2017-2021
9.    Global Lung Cancer Therapeutics Market Forecast: Breakup by Therapy Type (USD Million), 2022-2027
10.    Global Lung Cancer Therapeutics Historical Market: Breakup by Treatment Type (USD Million), 2017-2021
11.    Global Lung Cancer Therapeutics Market Forecast: Breakup by Treatment Type (USD Million), 2022-2027
12.    Global Lung Cancer Therapeutics Historical Market: Breakup by Region (USD Million), 2017-2021
13.    Global Lung Cancer Therapeutics Market Forecast: Breakup by Region (USD Million), 2022-2027
14.    North America Lung Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
15.    North America Lung Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Europe Lung Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Europe Lung Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Asia Pacific Lung Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
19.    Asia Pacific Lung Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
20.    Latin America Lung Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
21.    Latin America Lung Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
22.    Middle East and Africa Lung Cancer Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
23.    Middle East and Africa Lung Cancer Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
24.    Global Lung Cancer Therapeutics Market Structure

Key Questions Answered in the Report

The market for lung cancer therapeutics is expected to grow at a CAGR of 10.10% during the forecast period of 2022-2027.

The lung cancer therapeutics market is driven by the rising development of technology for treatment and diagnosis and an increasing number of cases due to the growth of the smoking population.

Governments are implementing plans to develop their healthcare infrastructure and organisations’ increasing focus on research and development to launch new and innovative treatment solutions are key trends in the market.

The regional markets for the global lung therapeutics market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

There are two main types of cancer available in the market for cancer therapeutics including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among others.

The market segments for lung cancer therapeutics, based on therapy, include Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy, among others.

These therapeutics find end-uses in hospitals, home care, and speciality clinics, among others.

The distribution channels in the market for lung cancer therapeutics include hospital pharmacies, retail pharmacies, and online.

If surgery is excluded from the options, combined chemotherapy and radiation therapy is the primary treatment used for lung cancer. For advanced lung cancers, radiation therapy can help in relieving pain and slowing down the advancement of cancer.

The United States Food and Drug Administration has approved Lumakras (sotorasib) for the treatment of non-small cell lung cancer in adult patients whose tumours have a specific genetic mutation known as KRAS G12C.

The key players in the market include Genentech, Inc., AstraZeneca PLC, Novartis AG., Merck KGaA, F. Hoffmann-La Roche Ltd, and Boehringer Ingelheim International GmbH, among others.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER